<DOC>
	<DOCNO>NCT03077477</DOCNO>
	<brief_summary>This Phase 1 study , assess safety , PK , pharmacodynamics ( PD ) orally-administered AMXT 1501 dicaprate normal healthy male volunteer . The study comprise total 8 cohort ; 4 single ascend dose ( SAD ) cohort , 1 Food Effect ( FE ) Crossover cohort , 3 multiple ascend dose ( MAD ) cohort . Tablets administer overnight fast ( 10 hour ) least 250 mL water . No food administer ( exception `` fed '' subject , see ) one hour thereafter . Each cohort total 6 subject : SAD MAD ( 2 subject receive placebo 4 subject receive active AMXT 1501 dicaprate ) ; FE crossover ( 6 subject receive active AMXT 1501 dicaprate ) .</brief_summary>
	<brief_title>Study Orally-Administered AMXT 1501 Dicaprate Normal Healthy Volunteers</brief_title>
	<detailed_description>The Phase 1 study , assess safety , PK , pharmacodynamics ( PD ) orally-administered AMXT 1501 dicaprate normal healthy male volunteer . The study comprise total 8 cohort ; 4 single ascend dose ( SAD ) cohort , 1 Food Effect ( FE ) Crossover cohort , 3 multiple ascend dose ( MAD ) cohort . Tablets administer overnight fast ( 10 hour ) least 250 mL water . No food administer ( exception `` fed '' subject , see ) one hour thereafter . Each cohort total 6 subject : SAD MAD ( 2 subject receive placebo 4 subject receive active AMXT 1501 dicaprate ) ; FE crossover ( 6 subject receive active AMXT 1501 dicaprate ) . SAD cohort define follow : - Cohort 1 : One placebo one AMXT 1501 dicaprate subject treat sentinel subject receive one tablet assign treatment . Assuming intolerance note least 3 day , remain cohort subject ( placebo , 1 subject AMXT 1501 dicaprate , 3 subject ) treat . - Cohort 2 : 2 subject 2 placebo 4 subject 2 AMXT 1501 dicaprate tablet - Cohort 3 : 2 subject 4 placebo 4 subject 4 AMXT 1501 dicaprate tablet - Cohort 4 : 2 subject 8 placebo 4 subject 8 AMXT 1501 dicaprate tablet FE Crossover : • Cohort 5 : 6 new subject randomize fed ( n=3 standard meal ) fast ( n=3 ) group administer high dose AMXT 1501 dicaprate tolerate previous cohort . First dose accompany assessment refer Period 1 . Subjects crossover opposite diet plan ( fed fast ) receive second administration study treatment dose level . The second dose assessment refer Period 2 . There 7-day washout dos administer Periods 1 2 . MAD cohort receive dose daily 14 consecutive day . Dosing contingent adequate tolerance Cohorts 1-5 . - Cohort 6 : 2 subject 2 placebo ; 4 subject 2 AMXT 1501 dicaprate tablet - Cohort 7 : 2 subject 4 placebo ; 4 subject 4 AMXT 1501 dicaprate tablet - Cohort 8 : 2 subject 8 placebo ; 4 subject 8 AMXT 1501 dicaprate tablet</detailed_description>
	<criteria>1 . Adult male age 18 55 year inclusive 18 30 kg/m2 body mass index ( BMI ) . 2 . Subjects healthy determine prestudy medical history , physical examination , 12 Lead ECG . 3 . Subjects whose clinical laboratory test result clinically relevant acceptable Investigator . 4 . Subjects negative hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) I II test screen . 5 . Subjects negative drug abuse alcohol test screen admission . 6 . Subjects nonsmoker least 1 month precede screen . 7 . Subjects able willing give write informed consent . 1 . History important clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . 2 . History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration study drug . 4 . Subjects history relevant drug hypersensitivity AMXT 1501 . 5 . Subjects history hearing loss . 6 . Subjects consume 21 unit alcohol week . ( unit = 1 glass wine [ 125 mL ] = 1 measure spirit = ½ pint beer ) 7 . Subjects significant infection know inflammatory process within 2 week dose febrile illness within 7 day dose . 8 . Subjects acute gastrointestinal symptom time screen admission ( e.g . nausea , vomit , diarrhea , heartburn ) . 9 . Subjects acute infection influenza time screen admission . 10 . Subjects agree use medically acceptable method contraception study 90 day last dose study drug 11 . Subjects use medication include antacid , analgesic ( exception occasional use 3 g acetaminophen day ) , herbal remedy ( e.g. , St. John 's Wort ) , vitamins mineral 2 week ( prescribe ) 1 week ( nonprescribed ) prior first administration study drug long medication long halflife . Occasional use paracetamol/acetaminophen allow minor pain headache . 12 . Subjects currently receive medication herbal supplement know potent inhibitor CYP3A4 potent inducer CYP3A4 ( 2 week prior first administration study drug ) . All subject must avoid concomitant use medication , herbal supplement and/or ingestion food know inducer/inhibitory effect CYP3A4 . 13 . Any intake grapefruit , grapefruit juice , product contain grapefruit within 14 day first administration study drug . 14 . Subjects use investigational drug clinical trial within 60 day screen visit . 15 . Subjects vegans medical dietary restriction . 16 . Subjects communicate reliably Investigator . 17 . Subjects unlikely cooperate requirement study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>